NST for patients with AML receiving grafts from matched sibling or matched unrelated donors.
| Total No. . | Donors . | Conditioning . | Status (No.) . | Engraftment . | Alive & Disease-free . | Center . |
|---|---|---|---|---|---|---|
| 20 | Sibling | Fludarabine 30 mg/m2/d × 6 | First CR (10) | 20/20 | 12/20 | Jerusalem, Israel |
| Busulfan 4 mg/kg/d × 2 | Second CR (7) | |||||
| ATG (Fresenius) 5-10 mg/kg × 4 | Relapse (3) | |||||
| 4 | Sibling | Fludarabine 30 mg/m2/d × 6 | Relapse (4) | 4/4 | 2/4 | Jerusalem, Israel |
| TBI 200cGy | ||||||
| 4 | Sibling | Fludarabine 30 mg/m2/d × 6 | Relapse after autoBMT | 4/4 | 2/4 | Jerusalem, Israel |
| Busulfan 4 mg/kg/d × 2 | ||||||
| ATG (Fresenius) 5-10 mg/kg × 4 | ||||||
| 4 | MUD | Fludarabine 30 mg/m2/d × 6 | First CR (2) | 4/4 | 3/4 | Jerusalem, Israel |
| Busulfan 4 mg/kg/d × 2 | Second CR (1) | |||||
| ATG (Fresenius) 5-10 mg/kg ×4 | Relapse (1) | |||||
| 29 | Sibling | Fludarabine 30 mg/m2/d × 4 | First CR (6)3 | 20/29 | 9/29 | Houston, Texas, USA |
| Ara-C 2 mg/m2 ×4 | Second CR (20 | (3 mixed chimeras) | ||||
| Idarubicin 12 mg/m2/d × 3 or 2 CDA 12 mg/m2/d × 5 | Relapse (21) | |||||
| Ara-C 1 g/m2/d × 5 | ||||||
| 16 | Sibling | Fludarabine 30 mg/m2/d × 4 | First CR (1)3 | 14/16 | 5/16 | Houston, Texas, USA |
| Melphalan 140 mg/m2/d | Second CR (1) | |||||
| Or 180 mg/m2/d | Relapse (16) | |||||
| 13 | MUD | Fludarabine 25 mg/m2/d × 5 | ≥ Second CR (3) | 12/13 | 5/13 | Houston, Texas, USA |
| Melphalan 180 mg/m2/d | Relapse (10) | |||||
| 4 | Sibling | Fludarabine 30 mg/m2/d × 6 | First CR (3) | 4/4 | 4/4 | Brno, CzechRepublic |
| Busulfan 4 mg/kg/d × 2 | Second CR (1) | |||||
| ATG (Fresenius) 5-10 mg/kg × 4 | ||||||
| 11 | Sibling | Fludarabine 30 mg/m2/d × 5 | First & Second CR (6) | 11/11 | 7/11 | Dresden, Germany |
| Busulfan 4 mg/kg/d × 2 or 3.3 mg/kg/d IU | Advanced (5) | |||||
| 16 | MUD | Fludarabine 30 mg/m2/d × 5 | First CR (5) | 16/16 | 7/16 | Dresden, Germany |
| Busulfan 3.3 mg/kg/d × 2 | Advanced (11) | (5 mixed chimeras) | ||||
| ATG (Merieux) 2.5 mg/kg/d × 4 | ||||||
| 7 | MUD | Fludarabine 30 mg/m2/d × 3 | Unavailable | 7/7 | 6/7 | Leipzig, Germany |
| TBI 200 cGy | ||||||
| 5 | Sibling | Fludarabine 30 mg/m2/d × 3 | Unavailable | 5/5 | 4/5 | Mexico City, Mexico |
| Busulfan 4 mg/kg/d 2 | (1 mixed chimera) | |||||
| Cyclophosphamide 350 mg/m2/d × 3 | ||||||
| 3 | Sibling | Fludarabine 30 mg/m2/d × 5 | Unavailable | 3/3 | 3/3 | Hammersmith London, UK |
| Busulfan 4 mg/kg/d × 2 | ||||||
| Abbreviations: ATG, antithymocyte globulin; MUD, matched unrelated donors; 2 CDA, 2 chlorodeoxyadenosine | ||||||
| Total No. . | Donors . | Conditioning . | Status (No.) . | Engraftment . | Alive & Disease-free . | Center . |
|---|---|---|---|---|---|---|
| 20 | Sibling | Fludarabine 30 mg/m2/d × 6 | First CR (10) | 20/20 | 12/20 | Jerusalem, Israel |
| Busulfan 4 mg/kg/d × 2 | Second CR (7) | |||||
| ATG (Fresenius) 5-10 mg/kg × 4 | Relapse (3) | |||||
| 4 | Sibling | Fludarabine 30 mg/m2/d × 6 | Relapse (4) | 4/4 | 2/4 | Jerusalem, Israel |
| TBI 200cGy | ||||||
| 4 | Sibling | Fludarabine 30 mg/m2/d × 6 | Relapse after autoBMT | 4/4 | 2/4 | Jerusalem, Israel |
| Busulfan 4 mg/kg/d × 2 | ||||||
| ATG (Fresenius) 5-10 mg/kg × 4 | ||||||
| 4 | MUD | Fludarabine 30 mg/m2/d × 6 | First CR (2) | 4/4 | 3/4 | Jerusalem, Israel |
| Busulfan 4 mg/kg/d × 2 | Second CR (1) | |||||
| ATG (Fresenius) 5-10 mg/kg ×4 | Relapse (1) | |||||
| 29 | Sibling | Fludarabine 30 mg/m2/d × 4 | First CR (6)3 | 20/29 | 9/29 | Houston, Texas, USA |
| Ara-C 2 mg/m2 ×4 | Second CR (20 | (3 mixed chimeras) | ||||
| Idarubicin 12 mg/m2/d × 3 or 2 CDA 12 mg/m2/d × 5 | Relapse (21) | |||||
| Ara-C 1 g/m2/d × 5 | ||||||
| 16 | Sibling | Fludarabine 30 mg/m2/d × 4 | First CR (1)3 | 14/16 | 5/16 | Houston, Texas, USA |
| Melphalan 140 mg/m2/d | Second CR (1) | |||||
| Or 180 mg/m2/d | Relapse (16) | |||||
| 13 | MUD | Fludarabine 25 mg/m2/d × 5 | ≥ Second CR (3) | 12/13 | 5/13 | Houston, Texas, USA |
| Melphalan 180 mg/m2/d | Relapse (10) | |||||
| 4 | Sibling | Fludarabine 30 mg/m2/d × 6 | First CR (3) | 4/4 | 4/4 | Brno, CzechRepublic |
| Busulfan 4 mg/kg/d × 2 | Second CR (1) | |||||
| ATG (Fresenius) 5-10 mg/kg × 4 | ||||||
| 11 | Sibling | Fludarabine 30 mg/m2/d × 5 | First & Second CR (6) | 11/11 | 7/11 | Dresden, Germany |
| Busulfan 4 mg/kg/d × 2 or 3.3 mg/kg/d IU | Advanced (5) | |||||
| 16 | MUD | Fludarabine 30 mg/m2/d × 5 | First CR (5) | 16/16 | 7/16 | Dresden, Germany |
| Busulfan 3.3 mg/kg/d × 2 | Advanced (11) | (5 mixed chimeras) | ||||
| ATG (Merieux) 2.5 mg/kg/d × 4 | ||||||
| 7 | MUD | Fludarabine 30 mg/m2/d × 3 | Unavailable | 7/7 | 6/7 | Leipzig, Germany |
| TBI 200 cGy | ||||||
| 5 | Sibling | Fludarabine 30 mg/m2/d × 3 | Unavailable | 5/5 | 4/5 | Mexico City, Mexico |
| Busulfan 4 mg/kg/d 2 | (1 mixed chimera) | |||||
| Cyclophosphamide 350 mg/m2/d × 3 | ||||||
| 3 | Sibling | Fludarabine 30 mg/m2/d × 5 | Unavailable | 3/3 | 3/3 | Hammersmith London, UK |
| Busulfan 4 mg/kg/d × 2 | ||||||
| Abbreviations: ATG, antithymocyte globulin; MUD, matched unrelated donors; 2 CDA, 2 chlorodeoxyadenosine | ||||||